Introduction {#sec1}
============

Cancer remains a major global burden of public health. According to the GLOBOCAN 2018, there will be an estimated 18.1 million new cancer cases and 9.6 million deaths in 2018 worldwide \[[@B1]\]. Various causes involving a variety of environmental and genetic factors lead to the development of cancer, although the exact mechanism of carcinogenesis has not been fully understood.

Vitamin D is a fat-soluble vitamin that is closely related to health \[[@B2]\]. They have the following three characteristics: (1) they are found in some natural foods; (2) humans store 7-dehydrocholesterol from cholesterol, which can be converted into vitamin D~3~ after exposure to ultraviolet light; (3) proper sunbathing is enough to satisfy the body's vitamin D need \[[@B2]\]. Vitamin D deficiency is a ubiquitous phenomenon. Nowadays, vitamin D is known to have functions beyond bone formation, including enhancing immune defense \[[@B3]\], inhibiting cell proliferation \[[@B4]\], inhibiting angiogenesis \[[@B5]\], inhibiting cell metastasis \[[@B6]\], and promoting tumor apoptosis \[[@B4]\]. In addition, vitamin D can reduce mortality in several malignancies \[[@B7]\]. Numerous studies have shown that vitamin D deficiency may be the reason why thousands of patients die prematurely from colon, breast, ovarian and other cancers each year \[[@B8]\].

Vitamin D is synthesized by a series of reactions catalyzed by many enzymes. CYP2R1 and CYP27A1 are 25-hydroxylase enzymes that first convert pro-vitamin D absorbed from the diet or produced in the skin after exposure to sunlight \[[@B11]\]. Next, CYP27B1, 1a-hydroxylase converts 25(OH)D into 1,25-dihydroxyvitamin D \[1,25(OH)~2~D~3~\] in the kidney \[[@B11]\]. Both vitamin D metabolites bind to vitamin D-binding proteins, also known as group-specific component (GC), which aid in the transport of vitamin D \[[@B11]\]. Genetic polymorphisms involving the vitamin D pathway may affect its activity, so if vitamin D does play a role in carcinogenesis, it may be associated with cancer.

Recently, genome-wide association studies (GWASs) have identified CYP27B1 and GC polymorphisms significantly associated with 25(OH)D concentrations \[[@B12]\]. The worldwide variation of CYP27B1 gene (Chromosome 12: 58,156,117-58,162,769 reverse strand) and of its polymorphism SNP rs4646537 (Chromosome 12:58157281 forward strand) and SNP rs3782130 (Chromosome 12:58161898 forward strand), and GC gene (Chromosome 4: 72,607,410-72,669,758 reverse strand) and of its polymorphism SNP rs4588 (Chromosome 4:72618323 forward strand) and SNP rs7041 (Chromosome 4:72618334 forward strand) were analyzed with data obtained from the public database 1000 Genomes Phase 3 Browser. According to the 1000 Genomes Project Phase 3 allele frequencies, the minor allele frequency (MAF) for rs4646537 is 4% in the combined population, the MAF for rs3782130 is 35% in the combined population, the MAF for rs4588 is 21% in the combined population, and the MAF for rs7041 is 38% in the combined population. Up to now, two common CYP27B1 polymorphisms (rs4646537, rs3782130) and two common GC polymorphisms (rs4588 and rs7041) were found to be associated with cancer risks, including breast cancer, non-small cell lung cancer, prostate cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. However, the results are inconsistent, probably because of the limited sample size. To better explore the precise relationship, we performed a meta-analysis and trial sequential analysis (TSA) to characterize the associations of GC (rs4588 and rs7041) and CYP27B1 (rs4646537, rs3782130) polymorphisms with cancer susceptibility.

Materials and methods {#sec2}
=====================

Literature retrieval {#sec2-1}
--------------------

We strictly searched EMBASE, PubMed, Web of Science, Wan Fang and CNKI electronic databases (up to 1 December 2018) for relevant studies exploring the associations of GC (rs4588 and rs7041) and CYP27B1 (rs4646537, rs3782130) polymorphisms with cancer risks according to the search strategy (Supplementary Table S1). Four authors (Man Zhu, Zhenzhao Luo, Zheqiong Tan and Hui Wang) independently searched and screened the search.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Enrolled studies should meet the following inclusion criteria: (A) Human-based research; (B) Case--control/cohort studies; (C) Effective data were available to compute odds ratio (OR), 95% confidence interval (CI) and *P*-value; (D) Involved in the associations of GC (rs4588 and rs7041) or CYP27B1 (rs4646537, rs3782130) polymorphisms (at least one polymorphism involved) with cancer risk; (E) The control group met Hardy--Weinberg equilibrium (HWE). When *P*\>0.05, the genetic balance of the population genes is indicated, indicating that the data are from the same Mendelian population \[[@B13]\]. In addition, the enrolled studies also need to meet the following exclusion criteria: (A) Case only or non-cancer subject only studies; (B) Duplicate publications; (C) Conference abstracts.

Data extraction {#sec2-3}
---------------

Two researchers (Tangwei Wu and Hui Hu) independently screened the detailed data from all enrolled studies. The following data were collected: first author name, issuing time, country, ethnicity, type of cancer, control source, genotyping method, numbers of cases and controls.

Quality assessment {#sec2-4}
------------------

Two researchers (Tangwei Wu and Hui Hu) assessed the quality of each investigation using the quality assessment criteria (Supplementary Table S2), which was derived from previously published meta-analysis of molecular association studies \[[@B14]\]. The quality assessment criteria cover the methodology for the ascertainment of cancer case (0--2 points), case representation (0--2 points), control representation (0--3 points), control selection (0--2 points), genotyping examination (0--2 points), conformity to HWE (0--1 point) and total sample size (0--3 points). Total scores ranged from 0 to 15, and studies with scores \>9 points were classified as high quality.

Statistical analysis {#sec2-5}
--------------------

Stata software (Stata, College Station, TX, U.S.A.), version 12.0, was used for statistical analysis. Associations of GC (rs4588 and rs7041) and CYP27B1 (rs4646537, rs3782130) polymorphisms with cancer risks were estimated by OR and 95% CI. Five different genetic models (dominant, recessive, homozygote, heterozygote and allele model) were used in current study. Statistical heterogeneity was counted by Cochrane Q-test and *P*-values, and random-effect model was used if *P*≤0.10 or *I^2^* ≥ 50%, otherwise, fixed-effect model was used. Stratification analysis was performed based on ethnicity, cancer type and the detection method of genotype. Publication bias (Begg's test and Egger's test) analyses and sensitivity analyses were used to evaluate the reliability of current study. *P*\<0.05 was considered statistically significant. For each significant finding, false-positive report probability (FPRP) analysis was performed using the method reported by Wacholder et al. \[[@B15]\]. We calculated FPRP assuming a prior probability of 0.1 as previously proposed \[[@B16]\]. We set 0.2 as an FPRP threshold and only result with FPRP-value \<0.2 was referred as noteworthy \[[@B16]\].

TSA {#sec2-6}
---

The poor effect of systematic or random errors may increase due to sparse data, which may eventually mislead results in meta-analyses \[[@B17]\]. In order to get more comprehensive results, TSA (Copenhagen Trial Unit, Denmark, 2011) was utilized. In our current study, an overall type-I error of 5%, a statistical test power of 80% and a 20% relative risk reduction was set up.

Results {#sec3}
=======

Screening process and characteristics of enrolled studies {#sec3-1}
---------------------------------------------------------

A total of 342 articles were obtained based on our search strategy. After reading titles and abstracts, 34 articles conformed to our inclusion criteria. After reading full-text, 21 articles were excluded, including 10 that did not describe GC (rs4588 and rs7041) or CYP27B1 (rs4646537, rs3782130) polymorphisms and cancer susceptibility, 2 that did not meet HWE, 4 case only or non-cancer subject only articles, and 5 that not provide detailed genotyping data. Finally, 13 eligible articles including 32 studies (15713 cases and 17304 controls) were enrolled in our current meta-analysis \[[@B18]\]. [Figure 1](#F1){ref-type="fig"} describes the screening process.

![Flow chart of the process for study identification and selection](bsr-39-bsr20190368-g1){#F1}

In general, sixteen studies included Caucasian populations, fourteen studies included Asian populations and two studies included African populations. TaqMan method was used in nine studies, PCR-RFLP method was used in eighteen studies, Illumina method was used in three studies and two studies used the SNPlex assay method. Ten studies reported the effects of GC polymorphisms in breast cancer, eight reported in digestive system tumor, three in non-small cell lung cancer and two in prostate cancer. Six studies reported the effects of CYP27B1 polymorphisms in prostate cancer, two reported in non-small cell lung cancer and one in digestive system tumor. The characteristics of these studies are listed in [Table 1](#T1){ref-type="table"}.

###### Characteristics of included studies

  First author              Year   Country     Ethnicity   Cancer type                  Control source   Genotyping method   Cases (AA/AB/BB)   Controls (AA/AB/BB)   HWE     Score
  ------------------------- ------ ----------- ----------- ---------------------------- ---------------- ------------------- ------------------ --------------------- ------- -------
  **GC (rs4588)**                                                                                                                                                             
  McCullough                2007   U.S.A.      Caucasian   Breast cancer                PB               TaqMan              240/202/48         246/186/44            0.307   12
  Anderson                  2011   Canada      Caucasian   Breast cancer                PB               PCR-RFLP            792/608/135        846/642/120           0.906   10
  Zhou-1                    2012   China       Asian       Hepatocellular carcinoma     HB               PCR-RFLP            101/111/25         142/148/25            0.110   7
  Zhou-2                    2012   China       Asian       Esophageal cancer            HB               PCR-RFLP            148/108/33         159/144/34            0.868   7
  Zhou-3                    2012   China       Asian       Gastric cancer               HB               PCR-RFLP            74/89/29           88/92/24              0.995   6
  Zhou-4                    2012   China       Asian       Colorectal cancer            HB               PCR-RFLP            113/100/33         182/134/15            0.117   7
  Reimers                   2015   U.S.A.      Caucasian   Breast cancer                PB               TaqMan              456/402/82         514/393/84            0.471   10
  Deschasaux                2016   France      Caucasian   Breast cancer                PB               TaqMan              101/89/30          227/181/42            0.498   8
  Deschasaux                2016   France      Caucasian   Prostate cancer              PB               TaqMan              82/63/20           71/43/10              0.344   7
  Wu                        2016   China       Asian       Non-small cell lung cancer   PB               PCR-RFLP            235/173/37         230/170/26            0.462   10
  **GC (rs7041)**                                                                                                                                                             
  McCullough                2007   U.S.A.      Caucasian   Breast cancer                PB               TaqMan              154/237/103        149/235/106           0.460   12
  Anderson                  2011   Canada      Caucasian   Breast cancer                PB               PCR-RFLP            288/782/558        486/760/309           0.703   10
  Zhou-1                    2012   China       Asian       Hepatocellular carcinoma     HB               PCR-RFLP            117/98/22          152/139/24            0.311   7
  Zhou-2                    2012   China       Asian       Esophageal cancer            HB               PCR-RFLP            148/119/22         188/128/21            0.899   7
  Zhou-3                    2012   China       Asian       Gastric cancer               HB               PCR-RFLP            99/89/16           98/86/10              0.105   6
  Zhou-4                    2012   China       Asian       Colorectal cancer            HB               PCR-RFLP            123/107/16         171/132/28            0.724   7
  Kong                      2014   China       Asian       Non-small cell lung cancer   PB               TaqMan              272/339/50         329/240/34            0.254   10
  Wang-1                    2014   Spain       Caucasian   Breast cancer                PB               Illumina            203/402/221        216/362/201           0.050   13
  Wang-2                    2014   Non-Spain   Caucasian   Breast cancer                PB               Illumina            42/61/27           73/116/35             0.320   11
  Clendenen                 2015   Sweden      Caucasian   Breast cancer                PB               Illumina            265/348/121        546/658/229           0.193   9
  Reimers                   2015   U.S.A.      Caucasian   Breast cancer                PB               TaqMan              239/470/186        311/474/193           0.609   10
  Deschasaux                2016   France      Caucasian   Prostate cancer              PB               TaqMan              19/63/45           39/76/50              0.337   7
  Wu                        2016   China       Asian       Non-small cell lung cancer   PB               PCR-RFLP            173/225/47         175/230/61            0.281   10
  **CYP27B1 (rs4646537)**                                                                                                                                                     
  Holick                    2007   U.S.A.      Caucasian   Prostate cancer              PB               SNPlex assay        546/38/0           497/43/2              0.310   14
  Holt-1                    2009   U.S.A.      Caucasian   Prostate cancer              PB               PCR-RFLP            319/324/61         314/325/77            0.601   10
  Holt-2                    2009   U.S.A.      African     Prostate cancer              PB               PCR-RFLP            85/28/2            50/16/1               0.826   7
  **CYP27B1 (rs3782130)**                                                                                                                                                     
  Holick                    2007   U.S.A.      Caucasian   Prostate cancer              PB               SNPlex assay        260/251/75         260/229/61            0.327   14
  Holt-1                    2009   U.S.A.      Caucasian   Prostate cancer              PB               PCR-RFLP            637/50/2           636/52/0              0.303   10
  Holt-2                    2009   U.S.A.      African     Prostate cancer              PB               PCR-RFLP            97/15/2            54/8/1                0.298   7
  Kong                      2014   China       Asian       Non-small cell lung cancer   PB               TaqMan              229/297/77         230/371/120           0.150   10
  Mahmoudi                  2014   Iran        Asian       Colorectal cancer            HB               PCR-RFLP            144/125/34         180/138/36            0.216   6
  Wu                        2016   China       Asian       Non-small cell lung cancer   PB               PCR-RFLP            194/149/83         187/163/45            0.300   10

Abbreviations: A, wild type; B, mutated type; HB, hospital-based control; PB, publication-based control.

Meta-analysis and TSA of rs7041 {#sec3-2}
-------------------------------

Nine publications including thirteen studies with 6916 cases and 7870 controls examined rrs7041 polymorphism. As shown in [Table 2](#T2){ref-type="table"}, we found that rs7041 polymorphism significantly increased cancer risk in four models: dominant (OR = 1.22, 95% CI = 1.03--1.44, *P*=0.019), recessive (OR = 1.27, 95% CI = 1.02--1.58, *P*=0.030), homozygote (OR = 1.41, 95% CI = 1.06--1.88, *P*=0.017, [Figure 2](#F2){ref-type="fig"}A), and allele (OR = 1.17, 95% CI = 1.02--1.33, *P*=0.022) models. When studies were stratified by ethnicity, significant associations were found in Asians (recessive, OR = 1.40, 95% CI = 1.11--1.77, *P*=0.005; homozygote, OR = 1.52, 95% CI = 1.19--1.93, *P*=0.001; heterozygote, OR = 1.28, 95% CI = 1.00--1.63, *P*=0.047; Allele, OR = 1.20, 95% CI = 1.09--1.32, *P*=0.000). Stratification analyses of cancer type indicated that rs7041 polymorphism increased the risk of non-small cell lung cancer (recessive, OR = 1.73, 95% CI = 1.05--2.84, *P*=0.031, [Figure 2](#F2){ref-type="fig"}B; homozygote, OR = 1.97, 95% CI = 1.38--2.81, *P*=0.000; allele, OR = 1.32, 95% CI = 1.09--1.60, *P*=0.004). Moreover, our data indicated that rs7041 polymorphism was also significantly associated with an increased risk of cancer in the studies with publication-based controls. The FPRP values for significant findings at different prior probability levels are shown in Supplementary Table S3. With the assumption of prior probability of 0.1, these statistically significant associations were noteworthy (FPRP-value \<0.2) for overall cancer risk (dominant and allele models), Asians (recessive, homozygote and allele models), non-small cell lung cancer (homozygote and allele models) and PCR-RFLP (heterozygote model) subgroups.

![Meta-analysis for the association between rs7041 polymorphism and cancer risk\
(**A**) Overall comparison (homozygote model); (**B**) stratification analysis by cancer type (recessive model).](bsr-39-bsr20190368-g2){#F2}

###### Meta-analysis of associations between the rs7041 polymorphism and cancer risk

  Model          Overall and Stratification analyses   Number of studies   Number of cases/controls   OR (95% CI)             *P*-value   Random/Fixed effect model   *P* for heterogeneity   *I^2^* (%)
  -------------- ------------------------------------- ------------------- -------------------------- ----------------------- ----------- --------------------------- ----------------------- ------------
  Dominant       Overall                               13                  6916/7870                  **1.22 (1.03, 1.44)**   **0.019**   Random                      0.000                   80.0
                 Caucasian                             7                   4834/5624                  1.25 (0.96, 1.63)       0.092       Random                      0.000                   87.3
                 Asian                                 6                   2082/2246                  1.19 (0.98, 1.45)       0.077       Random                      0.030                   59.7
                 Breast cancer                         6                   4707/5459                  1.21 (0.92, 1.60)       0.179       Random                      0.000                   89.2
                 Digestive system tumor                4                   976/1177                   1.08 (0.91, 1.28)       0.364       Fixed                       0.811                   0
                 Non-small cell lung cancer            2                   1106/1069                  1.38 (0.89, 2.14)       0.150       Random                      0.012                   84.1
                 Prostate cancer                       1                   127/165                    1.76 (0.96, 3.22)       0.067       Fixed                       \-                      \-
                 PB                                    9                   5940/6693                  **1.28 (1.04, 1.59)**   **0.023**   Random                      0.000                   85.2
                 HB                                    4                   976/1177                   1.08 (0.91, 1.28)       0.364       Fixed                       0.811                   0
                 PCR-RFLP                              6                   3049/3198                  1.23 (0.90, 1.68)       0.198       Random                      0.000                   86.2
                 TaqMan                                4                   2177/2236                  1.29 (0.95, 1.75)       0.102       Random                      0.002                   79.3
                 Illumina                              3                   1690/2436                  1.11 (0.97, 1.28)       0.119       Fixed                       0.796                   0
                 High quality (\>9)                    7                   5079/5095                  1.28 (0.99, 1.64)       0.057       Random                      0.000                   87.5
                 Low quality (≤9)                      6                   1837/2775                  1.11 (0.98, 1.25)       0.104       Fixed                       0.653                   0
  Recessive      Overall                               13                  6916/7870                  **1.27 (1.02, 1.58)**   **0.030**   Random                      0.000                   79.2
                 Caucasian                             7                   4834/5624                  1.21 (0.91, 1.62)       0.192       Random                      0.000                   88.0
                 Asian                                 6                   2082/2246                  **1.40 (1.11, 1.77)**   **0.005**   Fixed                       0.179                   35.2
                 Breast cancer                         6                   4707/5459                  1.21 (0.88, 1.66)       0.248       Random                      0.000                   90.0
                 Digestive system tumor                4                   976/1177                   1.16 (0.84, 1.61)       0.377       Fixed                       0.356                   7.4
                 Non-small cell lung cancer            2                   1106/1069                  **1.73 (1.05, 2.84)**   **0.031**   Random                      0.153                   51.1
                 Prostate cancer                       1                   127/165                    1.26 (0.77, 2.07)       0.354       Fixed                       \-                      \-
                 PB                                    9                   5940/6693                  **1.30 (1.01, 1.68)**   **0.045**   Random                      0.000                   85.1
                 HB                                    4                   976/1177                   1.16 (0.84, 1.61)       0.377       Fixed                       0.356                   7.4
                 PCR-RFLP                              6                   3049/3198                  **1.55 (1.10, 2.19)**   **0.013**   Random                      0.017                   63.8
                 TaqMan                                4                   2177/2236                  1.06 (0.90, 1.24)       0.497       Fixed                       0.498                   0
                 Illumina                              3                   1690/2436                  1.07 (0.91, 1.25)       0.400       Fixed                       0.589                   0
                 High quality (\>9)                    7                   5079/5095                  1.35 (0.99, 1.85)       0.055       Random                      0.000                   87.6
                 Low quality (≤9)                      6                   1837/2775                  1.10 (0.92, 1.32)       0.298       Fixed                       0.571                   0
  Homozygote     Overall                               13                  6916/7870                  **1.41 (1.06, 1.88)**   **0.017**   Random                      0.000                   84.5
                 Caucasian                             7                   4834/5624                  1.38 (0.92, 2.07)       0.124       Random                      0.000                   91.5
                 Asian                                 6                   2082/2246                  **1.52 (1.19, 1.93)**   **0.001**   Fixed                       0.203                   31.1
                 Breast cancer                         6                   4707/5459                  1.33 (0.85, 2.06)       0.213       Random                      0.000                   92.9
                 Digestive system tumor                4                   976/1177                   1.19 (0.85, 1.67)       0.315       Fixed                       0.420                   0
                 Non-small cell lung cancer            2                   1106/1069                  **1.97 (1.38, 2.81)**   **0.000**   Fixed                       0.514                   0
                 Prostate cancer                       1                   127/165                    1.85 (0.94, 3.65)       0.077       Fixed                       \-                      \-
                 PB                                    9                   5940/6693                  **1.49 (1.05, 2.09)**   **0.024**   Random                      0.000                   89.0
                 HB                                    4                   976/1177                   1.19 (0.85, 1.67)       0.315       Fixed                       0.420                   51.1
                 PCR-RFLP                              6                   3049/3198                  **1.66 (1.03, 2.69)**   **0.039**   Random                      0.000                   79.7
                 TaqMan                                4                   2177/2236                  1.25 (0.92, 1.69)       0.157       Random                      0.078                   56
                 Illumina                              3                   1690/2436                  1.14 (0.96, 1.37)       0.145       Fixed                       0.816                   0
                 High quality (\>9)                    7                   5079/5095                  1.52 (0.99, 2.30)       0.052       Random                      0.000                   90.7
                 Low quality (≤9)                      6                   1837/2775                  1.17 (0.96, 1.43)       0.116       Fixed                       0.435                   0
  Heterozygote   Overall                               13                  6916/7870                  1.18 (0.98, 1.43)       0.081       Random                      0.000                   68.4
                 Caucasian                             7                   4834/5624                  1.14 (0.90, 1.45)       0.279       Random                      0.000                   79.1
                 Asian                                 6                   2082/2246                  **1.28 (1.00, 1.63)**   **0.047**   Fixed                       0.103                   45.3
                 Breast cancer                         6                   4707/5459                  1.15 (0.88, 1.49)       0.303       Random                      0.000                   82.5
                 Digestive system tumor                4                   976/1177                   1.12 (0.80, 1.58)       0.508       Fixed                       0.322                   14.0
                 Non-small cell lung cancer            2                   1106/1069                  1.52 (0.70, 3.29)       0.285       Random                      0.032                   78.4
                 Prostate cancer                       1                   127/165                    1.09 (0.64, 1.83)       0.758       Fixed                       \-                      \-
                 PB                                    9                   5940/6693                  1.20 (0.96, 1.49)       0.110       Random                      0.000                   76.6
                 HB                                    4                   976/1177                   1.12 (0.80, 1.58)       0.508       Fixed                       0.322                   14.0
                 PCR-RFLP                              6                   3049/3198                  **1.48 (1.09, 2.01)**   **0.013**   Random                      0.071                   50.7
                 TaqMan                                4                   2177/2236                  0.99 (0.84, 1.17)       0.904       Fixed                       0.975                   0
                 Illumina                              3                   1690/2436                  1.03 (0.87, 1.21)       0.769       Fixed                       0.463                   0
                 High quality (\>9)                    7                   5079/5095                  1.25 (0.96, 1.63)       0.103       Random                      0.000                   80.6
                 Low quality (≤9)                      6                   1837/2775                  1.05 (0.86, 1.27)       0.639       Fixed                       0.580                   0
  Allele         Overall                               13                  6916/7870                  **1.17 (1.02, 1.33)**   **0.022**   Random                      0.000                   85.2
                 Caucasian                             7                   4834/5624                  1.17 (0.95, 1.44)       0.133       Random                      0.000                   91.7
                 Asian                                 6                   2082/2246                  **1.20 (1.09, 1.32)**   **0.000**   Fixed                       0.137                   40.2
                 Breast cancer                         6                   4707/5459                  1.15 (0.92, 1.44)       0.217       Random                      0.000                   93.1
                 Digestive system tumor                4                   976/1177                   1.08 (0.94, 1.23)       0.283       Fixed                       0.750                   0
                 Non-small cell lung cancer            2                   1106/1069                  **1.32 (1.09, 1.60)**   **0.004**   Random                      0.144                   53.1
                 Prostate cancer                       1                   127/165                    1.33 (0.95, 1.85)       0.096       Fixed                       \-                      \-
                 PB                                    9                   5940/6693                  **1.20 (1.02, 1.42)**   **0.029**   Random                      0.000                   89.4
                 HB                                    4                   976/1177                   1.08 (0.94, 1.23)       0.283       Fixed                       0.750                   0
                 PCR-RFLP                              6                   3049/3198                  1.21 (0.95, 1.53)       0.121       Random                      0.000                   87.0
                 TaqMan                                4                   2177/2236                  1.16 (0.96, 1.41)       0.130       Random                      0.004                   77.6
                 Illumina                              3                   1690/2436                  1.07 (0.98, 1.17)       0.128       Fixed                       0.919                   0
                 High quality (\>9)                    7                   5079/5095                  1.21 (0.99, 1.48)       0.057       Random                      0.000                   91.1
                 Low quality (≤9)                      6                   1837/2775                  1.08 (0.99, 1.18)       0.086       Fixed                       0.728                   0

Abbreviations: HB, hospital-based control; PB, publication-based control. Bold values are statistically significant (*P*\<0.05).

As shown in [Figure 3](#F3){ref-type="fig"}A, although the total number of cases did not exceed the O'Brien--Fleming boundary, the cumulative Z-curve exceeded the test sequence monitoring boundary, which verified that rs7041 was significantly associated with cancer susceptibility.

![TSAs of the association between rs4588, rs7041, rs3782130 and rs4646537 polymorphisms (dominant model) and cancer risk\
(**A**) rs7041; (**B**) rs4588; (**C**) rs3782130; (**D**) rs4646537.](bsr-39-bsr20190368-g3){#F3}

Meta-analysis and TSA of rs4588 {#sec3-3}
-------------------------------

Seven publications including ten studies with 4759 cases and 5262 controls examined rs4588 polymorphism. As shown in [Table 3](#T3){ref-type="table"}, we found that rs4588 polymorphism significantly increased cancer risk in all five models: dominant (OR = 1.10, 95% CI = 1.02--1.19, *P*=0.016), recessive (OR = 1.27, 95% CI = 1.11--1.46, *P*=0.001), homozygote (OR = 1.31, 95% CI = 1.13--1.51, *P*=0.000, [Figure 4](#F4){ref-type="fig"}A), heterozygote (OR = 1.23, 95% CI = 1.06--1.42, *P*=0.005), and allele (OR = 1.11, 95% CI = 1.05--1.18, *P*=0.001) models. Stratification analyses indicated that rs4588 polymorphism significantly increased cancer risk in Caucasians (dominant, OR = 1.10, 95% CI = 1.01--1.21, *P*=0.040; recessive, OR = 1.17, 95% CI = 1.00--1.39, *P*=0.049; homozygote, OR = 1.22, 95% CI = 1.02--1.45, *P*=0.026; allele, OR = 1.10, 95% CI = 1.02--1.18, *P*=0.015) and Asians (recessive, OR = 1.51, 95% CI = 1.18--1.94, *P*=0.001; homozygote, OR = 1.56, 95% CI = 1.06--2.29, *P*=0.024; heterozygote, OR = 1.51, 95% CI = 1.16--1.96, *P*=0.002, [Figure 4](#F4){ref-type="fig"}B). When studies were stratified by cancer type, significant associations were found in breast cancer (dominant, OR = 1.10, 95% CI = 1.00--1.21, *P*=0.046; homozygote, OR = 1.20, 95% CI = 1.00--1.43, *P*=0.047; allele, OR = 1.09, 95% CI = 1.01--1.17, *P*=0.030) and digestive system tumor (recessive, OR = 1.58, 95% CI = 1.02--2.46, *P*=0.042; heterozygote, OR = 1.54, 95% CI = 1.15--2.08, *P*=0.004), but not in prostate cancer and non-small cell lung cancer. Moreover, when studies were stratified by quality score, an increased cancer risk was observed in high quality subgroup in all five genetic models. When studies were stratified by control source and genotyping method, significant associations were found in publication-based controls, hospital-based controls and PCR-RFLP method, but not in TaqMan method. The FPRP values for significant findings at different prior probability levels are shown in Supplementary Table S4. With the assumption of prior probability of 0.1, these statistically significant associations were noteworthy for overall cancer risk (in all five models), Caucasians (homozygote and allele models), Asians (recessive and heterozygote models), digestive system tumor (heterozygote model), breast cancer (allele model) publication-based controls (homozygote and allele models), PCR-RFLP (recessive, homozygote, heterozygote and allele models) and high quality (in all five models) subgroups.

![Meta-analysis for the association between rs4588 polymorphism and cancer risk\
(**A**) Overall comparison (homozygote model); (**B**) stratification analysis by ethnicity (heterozygote model).](bsr-39-bsr20190368-g4){#F4}

###### Meta-analysis of associations between the rs4588 polymorphism and cancer risk

  Model          Overall and Stratification analyses   Number of studies   Number of cases/controls   OR (95% CI)             *P*-value   Random/Fixed effect model   *P* for heterogeneity   *I^2^* (%)
  -------------- ------------------------------------- ------------------- -------------------------- ----------------------- ----------- --------------------------- ----------------------- ------------
  Dominant       Overall                               10                  4759/5262                  **1.10 (1.02, 1.19)**   **0.016**   Fixed                       0.614                   0
                 Caucasian                             5                   3350/3649                  **1.10 (1.01, 1.21)**   **0.040**   Fixed                       0.770                   0
                 Asian                                 5                   1409/1613                  1.10 (0.95, 1.27)       0.214       Fixed                       0.248                   26.0
                 Breast cancer                         4                   3185/3525                  **1.10 (1.00, 1.21)**   **0.046**   Fixed                       0.791                   0
                 Digestive system tumor                4                   964/1187                   1.12 (0.94, 1.32)       0.210       Fixed                       0.154                   42.9
                 Prostate cancer                       1                   165/124                    1.36 (0.85, 2.17)       0.203       Fixed                       \-                      \-
                 Non-small cell lung cancer            1                   445/426                    1.05 (0.80, 1.37)       0.727       Fixed                       \-                      \-
                 PB                                    6                   3795/4075                  **1.10 (1.00, 1.20)**   **0.040**   Fixed                       0.857                   0
                 HB                                    4                   964/1187                   1.12 (0.94, 1.32)       0.210       Fixed                       0.154                   42.9
                 PCR-RFLP                              6                   2944/3221                  1.07 (0.97, 1.18)       0.202       Fixed                       0.342                   11.4
                 TaqMan                                4                   1815/2041                  1.16 (0.98, 1.32)       0.083       Fixed                       0.899                   0
                 High quality (\>9)                    4                   3410/3501                  **1.16 (1.02, 1.32)**   **0.047**   Fixed                       0.314                   15.5
                 Low quality (≤9)                      6                   1349/1761                  1.08 (0.98, 1.19)       0.109       Fixed                       0.859                   0
  Recessive      Overall                               10                  4759/5262                  **1.27 (1.11, 1.46)**   **0.001**   Fixed                       0.204                   26.1
                 Caucasian                             5                   3350/3649                  **1.17 (1.00, 1.39)**   **0.049**   Fixed                       0.652                   0
                 Asian                                 5                   1409/1613                  **1.51 (1.18, 1.94)**   **0.001**   Fixed                       0.128                   44.1
                 Breast cancer                         4                   3185/3525                  1.16 (0.98, 1.37)       0.092       Fixed                       0.588                   0
                 Digestive system tumor                4                   964/1187                   **1.58 (1.02, 2.46)**   **0.042**   Random                      0.070                   57.5
                 Prostate cancer                       1                   165/124                    1.57 (0.71, 3.49)       0.266       Fixed                       \-                      \-
                 Non-small cell lung cancer            1                   445/426                    1.40 (0.83, 2.35)       0.210       Fixed                       \-                      \-
                 PB                                    6                   3795/4075                  **1.19 (1.02, 1.40)**   **0.029**   Fixed                       0.724                   0
                 HB                                    4                   964/1187                   **1.58 (1.02, 2.46)**   **0.042**   Random                      0.070                   57.5
                 PCR-RFLP                              6                   2944/3221                  **1.35 (1.13, 1.61)**   **0.001**   Fixed                       0.121                   42.6
                 TaqMan                                4                   1815/2041                  1.16 (0.93, 1.44)       0.189       Fixed                       0.488                   0
                 High quality (\>9)                    4                   3410/3501                  **1.55 (1.23, 1.96)**   **0.000**   Fixed                       0.216                   29.2
                 Low quality (≤9)                      6                   1349/1761                  1.14 (0.96, 1.36)       0.121       Fixed                       0.758                   0
  Homozygote     Overall                               10                  4759/5262                  **1.31 (1.13, 1.51)**   **0.000**   Fixed                       0.173                   29.6
                 Caucasian                             5                   3350/3649                  **1.22 (1.02, 1.45)**   **0.026**   Fixed                       0.683                   0
                 Asian                                 5                   1409/1613                  **1.56 (1.06, 2.29)**   **0.024**   Random                      0.072                   53.4
                 Breast cancer                         4                   3185/3525                  **1.20 (1.00, 1.43)**   **0.047**   Fixed                       0.671                   0
                 Digestive system tumor                4                   964/1187                   1.62 (0.98, 2.68)       0.061       Random                      0.037                   64.5
                 Prostate cancer                       1                   165/124                    1.73 (0.76, 3.94)       0.191       Fixed                       \-                      \-
                 Non-small cell lung cancer            1                   445/426                    1.39 (0.82, 2.38)       0.224       Fixed                       \-                      \-
                 PB                                    6                   3795/4075                  **1.23 (1.05, 1.45)**   **0.013**   Fixed                       0.775                   0
                 HB                                    4                   964/1187                   1.62 (0.98, 2.68)       0.061       Random                      0.037                   64.5
                 PCR-RFLP                              6                   2944/3221                  **1.45 (1.08, 1.94)**   **0.014**   Random                      0.072                   50.5
                 TaqMan                                4                   1815/2041                  1.23 (0.98, 1.54)       0.077       Fixed                       0.518                   0
                 High quality (\>9)                    4                   3410/3501                  **1.59 (1.25, 2.04)**   **0.000**   Fixed                       0.130                   41.3
                 Low quality (≤9)                      6                   1349/1761                  1.18 (0.99, 1.40)       0.069       Fixed                       0.892                   0
  Heterozygote   Overall                               10                  4759/5262                  **1.23 (1.06, 1.42)**   **0.005**   Fixed                       0.314                   14.0
                 Caucasian                             5                   3350/3649                  1.12 (0.94, 1.34)       0.203       Fixed                       0.662                   0
                 Asian                                 5                   1409/1613                  **1.51 (1.16, 1.96)**   **0.002**   Fixed                       0.305                   17.2
                 Breast cancer                         4                   3185/3525                  1.11 (0.93, 1.33)       0.251       Fixed                       0.534                   0
                 Digestive system tumor                4                   964/1187                   **1.54 (1.15, 2.08)**   **0.004**   Fixed                       0.191                   36.8
                 Prostate cancer                       1                   165/124                    1.37 (0.58, 3.20)       0.474       Fixed                       \-                      \-
                 Non-small cell lung cancer            1                   445/426                    1.40 (0.81, 2.41)       0.227       Fixed                       \-                      \-
                 PB                                    6                   3795/4075                  1.15 (0.97, 1.35)       0.113       Fixed                       0.704                   0
                 HB                                    4                   964/1187                   1.24 (0.99, 1.65)       0.127       Fixed                       0.191                   36.8
                 PCR-RFLP                              6                   2944/3221                  **1.34 (1.12, 1.62)**   **0.002**   Fixed                       0.279                   20.5
                 TaqMan                                4                   1815/2041                  1.07 (0.85, 1.35)       0.546       Fixed                       0.552                   0
                 High quality (\>9)                    4                   3410/3501                  **1.51 (1.18, 1.93)**   **0.001**   Fixed                       0.438                   0
                 Low quality (≤9)                      6                   1349/1761                  1.11 (0.92, 1.32)       0.272       Fixed                       0.593                   0
  Allele         Overall                               10                  4759/5262                  **1.11 (1.05, 1.18)**   **0.001**   Fixed                       0.284                   17.3
                 Caucasian                             5                   3350/3649                  **1.10 (1.02, 1.18)**   **0.015**   Fixed                       0.685                   0
                 Asian                                 5                   1409/1613                  1.15 (0.99, 1.35)       0.077       Random                      0.086                   50.9
                 Breast cancer                         4                   3185/3525                  **1.09 (1.01, 1.17)**   **0.030**   Fixed                       0.764                   0
                 Digestive system tumor                4                   964/1187                   1.18 (0.95, 1.45)       0.131       Random                      0.049                   61.8
                 Prostate cancer                       1                   165/124                    1.33 (0.92, 1.93)       0.127       Fixed                       \-                      \-
                 Non-small cell lung cancer            1                   445/426                    1.09 (0.88, 1.35)       0.425       Fixed                       \-                      \-
                 PB                                    6                   3795/4075                  **1.10 (1.02, 1.17)**   **0.010**   Fixed                       0.809                   0
                 HB                                    4                   964/1187                   1.18 (0.95, 1.45)       0.131       Random                      0.049                   61.8
                 PCR-RFLP                              6                   2944/3221                  **1.10 (1.02, 1.19)**   **0.014**   Fixed                       0.104                   45.3
                 TaqMan                                4                   1815/2041                  1.13 (0.97, 1.25)       0.087       Random                      0.085                   50.6
                 High quality (\>9)                    4                   3410/3501                  **1.19 (1.07, 1.33)**   **0.001**   Fixed                       0.137                   40.0
                 Low quality (≤9)                      6                   1349/1761                  1.08 (0.99, 1.16)       0.054       Fixed                       0.988                   0

Abbreviations: HB, hospital-based control; PB, publication-based control. Bold values are statistically significant (*P*\<0.05).

To analyze the reliability of our results, we performed a TSA. As shown in [Figure 3](#F3){ref-type="fig"}B, the cumulative number of cases did not meet the O'Brien--Fleming boundary and test sequence monitoring boundary. Current TSA results suggested that more sample size was still needed for more robust results.

Meta-analysis and TSA of rs4646537 and rs3782130 {#sec3-4}
------------------------------------------------

Two publications including three studies with 1403 cases and 1325 controls examined rs4646537 polymorphism; five publications including six studies with 2721 cases and 2761 controls examined rs3782130 polymorphism. As shown in Supplementary Table S5, we found these two polymorphisms were not associated with cancer risk.

As for rs4646537 and rs3782130, the cumulative number of cases did not exceed the O'Brien--Fleming boundary and test sequence monitoring boundary ([Figure 3](#F3){ref-type="fig"}C,D). Therefore, more sample sizes were still needed for more robust results.

Publication bias and sensitivity analysis {#sec3-5}
-----------------------------------------

As showed in Supplementary Figure S1 and [Table 4](#T4){ref-type="table"}, Begg's and Egger's tests indicated that there was no evidence of significant publication bias in our current meta-analysis. Sensitivity analysis found that none of the single study significantly changed the final conclusion (Supplementary Figure S2).

###### Begg's and Egger's tests for publication bias

  Model          rs4588   rs7041   rs4646537   rs3782130                           
  -------------- -------- -------- ----------- ----------- ------- ------- ------- -------
  Dominant       0.669    0.573    0.502       0.221       0.602   0.838   0.707   0.727
  Recessive      0.132    0.119    0.200       0.498       0.546   0.588   0.310   0.945
  Homozygote     0.231    0.124    0.161       0.362       0.573   0.597   0.452   0.833
  Heterozygote   0.107    0.132    0.127       0.722       1.000   0.562   0.348   0.736
  Allele         0.208    0.130    0.200       0.166       0.609   0.721   0.851   0.947

Discussion {#sec4}
==========

It has long been clear that genetics has the ability to intervene in the cancer risk in the coming decades. Since polymorphism is the most important cause of human genetic material and information variation, the specific relationship between polymorphisms and cancer susceptibility has attracted widespread attention. With the rapid development of medical science and technology, the field of tumor genetic susceptibility has gradually attracted great interest, and the research on tumor genetic polymorphism is also increasing. Genetic polymorphisms involving the vitamin D pathway has become an important class of genes in the extensive study of polymorphisms in risk factors associated with malignant tumors.

CYP27B1 and GC are two important enzymes involved in vitamin D binding and transport. Nowadays, a growing body of evidence suggests that differential expression of CYP27B1 and GC may play an important role in carcinogenesis development. Reduced CYP27B1 gene expression level has been found in various tumors, including prostate cancer \[[@B31]\], non-small cell lung cancer \[[@B23]\]. Whitlatch et al. \[[@B32]\] investigated CYP27B1 expression in normal prostate, prostatic hyperplasia and prostate cancer, and they found that normal prostate exhibited the highest expression of CYP27B1, while its expression was decreased in the following order: prostatic hyperplasia and prostate cancer. These findings suggest that the malignant progression of prostate tissue certainly reduces CYP27B1 expression. Furthermore, Kong et al. \[[@B23]\] found that non-small cell lung cancer patients with high CYP27B1 expression had better overall survival than those with low CYP27B1, which indicated that low CYP27B1 expression was also correlated with a poorer prognosis. In addition, there are two common single nucleotide polymorphisms (rs7041 and rs4588) in GC gene. In the previous reports, genetic variants in the GC gene, including rs7041 and rs4588, have been investigated in breast cancer \[[@B18],[@B22],[@B25]\], non-small cell lung cancer \[[@B21]\], prostate cancer \[[@B26]\] and digestive system tumor \[[@B27]\]. However, to date, there is no systematic evaluation on how CYP27B1 and GC polymorphisms are involved in development of cancers.

Our data found that rs4588 was significantly associated with an increased risk of cancer susceptibility, and current result was confirmed by FPRP and TSA analyses. Among these studies, there were four studies on breast cancer, four on digestive system tumor, one on prostate cancer and one on non-small cell lung cancer. Stratified analyses by cancer type revealed a significant association between rs4588 and breast cancer and digestive system tumor, but not in prostate cancer and non-small cell lung cancer. However, our outcomes were different from the results shown by Anderson et al. \[[@B18]\], McCullough et al. \[[@B19]\], Reimers et al. \[[@B22]\], and Deschasaux et al. \[[@B25]\], who demonstrated that rs4588 polymorphism was not associated with breast cancer. This discrepancy may be caused by the limited sample size. Anderson et al. \[[@B18]\] included only 3143 subjects (1535 cases and 1608 controls), McCullough et al. \[[@B19]\] included only 966 subjects (490 cases and 476 controls), Reimers et al. \[[@B22]\] included only 1931 subjects (940 cases and 991 controls), Deschasaux et al. \[[@B25]\] included only 670 subjects (220 cases and 450 controls), which may lack sufficient power to support or deny an association. Previous studies also focused on the relationship between the rs4588 and digestive system tumor. However, our outcomes were different from previous study \[[@B27]\], which indicated that rs4588 polymorphism was not associated with hepatocellular carcinoma, esophageal cancer and gastric cancer. Possible reasons for this difference could be explained as the limited sample size. There was only one study for hepatocellular carcinoma, esophageal cancer and gastric cancer, which was far from enough to obtain trustworthy results. Based on current TSA results, more studies by standardized unbiased methods are required to offer more detailed data.

As for rs7041, we found that this polymorphism significantly increased cancer risk. Stratification analyses of ethnicity suggested rs7041 increased cancer risk in Asians, but not in Caucasians. Possible reasons can be explained as the different genetic backgrounds of cancer across ethnicities. In this meta-analysis, the pooled rs7041 C allele frequency of the controls showed a large difference across ethnicities (Asians: 30.2%; Caucasians: 45.4%), which may possibly affect the relationships between rs7041 polymorphism and cancer risk among different racial subgroups. Moreover, when studies were stratified by cancer type, we also found that rs7041 polymorphism was significantly associated with an increased risk in the non-small cell lung cancer. However, most subgroups had insufficient numbers, which may attenuate the statistical power. Our results were partially consistent with the consequence of the study by Wang et al. \[[@B20]\], which reported that there was no significant association between rs7041 and breast cancer in Asians and Caucasians. However, study by Reimers et al \[[@B22]\]. suggested that rs7041 was associated with an increased risk of breast cancer in Caucasians. It is noteworthy that Yao et al. \[[@B33]\] indicated that increased polymorphism may be related to the higher prevalence of estrogen receptor (ER)-negative but not ER-positive breast cancer. At present, a large number of researches indicated that there were important differences in genetic susceptibility between ER-negative and ER-positive breast cancer \[[@B11]\]. Therefore, it is reasonable to hypothesize that rs7041 polymorphism may have a specific effect on the susceptibility to ER-negative breast cancer. Of note, due to limited data, lack of further evaluation between rs7041 and ER-negative and ER-positive breast cancer prevented our comprehensive understanding. Further large-cohort and well-designed studies are necessary to identify the possible association between them. With respect to the remaining two polymorphisms, we failed to find any associations between rs4646537 and rs3782130 and cancer risk. Given the limited sample size, our results should be interpreted with caution.

In general, current analysis has the following advantages: (1) Our research results were validated based on TSA to ensure the reliability of the results. (2) All included studies were consistent with the HWE balance law, which may improve the reliability of our study. (3): This system evaluation is the first analysis of reviewing the relationships between CYP27B1 (rs4646537, rs3782130) and GC (rs4588 and rs7041) polymorphisms with cancer susceptibility. (4) To avoid false positive findings, FPRP analyses were used for all significant findings observed in our study. However, current study still has the following shortcomings: (1) The subjects we included were limited to Caucasians and Asians, and the results of the present study still lack information from other ethnic groups, which may lead to publication bias. (2) The number of studies on rs4646537, rs3782130, rs4588 and rs7041 was relatively small in some subgroups, which may create significant or insignificant results by chance. (3) In some included studies, detailed information (e.g., radiation exposure, carcinogen, smoking and other risk factors) was not gathered, which further prevented the stratification analyses. Thus, a larger sample size, multi-racial, multi-center standardized research is needed to provide more detailed data in the future.

Conclusions {#sec5}
===========

In conclusion, this systematical meta-analysis indicated that rs4588 and rs7041 polymorphisms play important roles in cancer pathogenesis, especially in non-small cell lung cancer, breast cancer and digestive system tumor, which were noteworthy findings as evaluated by FPRP. However, the other two polymorphisms (rs4646537 and rs3782130) are not associated with cancer risk. Further well-designed studies are necessary to validate our results.
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